Economic evaluation of alternative PCV13 vaccination strategies in Guangxi, China: a decision tree-Markov model study [0.03%]
中国广西接种肺炎球菌结合疫苗替代方案的经济评估：决策树-马尔可夫模型研究
Quan He,Bangjun Pang,Zhengqin Su et al.
Quan He et al.
Background: Pneumococcal disease remains a major cause of morbidity and mortality among children under five years of age, particularly in settings with low vaccine coverage. In China, the 13-valent pneumococcal conjugate ...
Fani Ladomenou,Michail Matalliotakis
Fani Ladomenou
Immunogenicity and safety of serum-free rabies vaccine for human use with simulated post-exposure schedules: A randomized, double-blind, active-controlled phase III clinical trial [0.03%]
一种人用模拟接触后暴露于狂犬病毒情况下无血清狂犬疫苗免疫原性和安全性的随机、双盲、阳性对照III期临床试验
Yulin Jing,Xiaoqiang Chang,Zhongqiang Jin et al.
Yulin Jing et al.
Background: Rabies is a fatal zoonotic disease that can be effectively prevented through timely postexposure prophylaxis (PEP). Serum-free rabies vaccines may theoretically reduce risks associated with animal-derived comp...
Impact of antigen and carrier substitution on the molecular weight and immunogenicity of the Pfs230D1-CRM197 malaria transmission-blocking vaccine [0.03%]
抗原和载体替换对Pfs230D1-CRM197疟疾传播阻断疫苗分子量及免疫原性的影响
Puthupparampil V Scaria,Beth Chen,Olga Muratova et al.
Puthupparampil V Scaria et al.
A protein-protein conjugate of Pfs230D1-CRM197 is currently being developed as a malaria transmission-blocking vaccine. To generate the conjugate, antigen and carrier are substituted with a defined number of sulfhydryl and maleimide groups ...
Estimating the impact of Shigella vaccines on growth outcomes and implications for clinical trial design [0.03%]
志贺氏菌疫苗对生长发育影响的评估及其对临床试验设计的意义
Allison Codi,Elizabeth Rogawski McQuade,David Benkeser
Allison Codi
Background: The value proposition for Shigella vaccines is strengthened by the potential for vaccines to prevent linear growth faltering. However, because expected effect sizes in Phase 3 vaccine trials are small due to l...
The cost of respiratory syncytial virus (RSV) across all ages to the Australian healthcare system [0.03%]
呼吸道合胞病毒(RSV)对澳大利亚医疗系统的经济负担研究——所有年龄段的成本分析
Kishor K Paul,Anthony T Newall
Kishor K Paul
Introduction: Respiratory syncytial virus (RSV) causes a spectrum of respiratory illnesses, including severe disease associated with substantial healthcare costs. To date Australian cost-of-illness studies have focused on...
Cost-effectiveness analysis of a hypothetical vaccine for schistosomiasis in Madagascar and Burkina Faso [0.03%]
一种假想的防治血吸虫病疫苗的成本效益分析——马达加斯加和布基纳法索案例研究
Yongha Hwang,Gbènonminvo Enoch Cakpo,Njariharinjakamampionona Rakotozandrindrainy et al.
Yongha Hwang et al.
Background: Schistosomiasis, a major neglected tropical disease, affects millions of people worldwide. Although mass drug administration with praziquantel remains the primary control strategy, vaccines are currently under...
Herpesvirus of Turkeys (HVT) vaccine confers limited protection against the cellular changes induced by very virulent plus Marek's disease virus (vv + MDV) strains in commercial meat-type chickens [0.03%]
火鸡疱疹病毒(HVT)疫苗对商业型肉用仔鸡 vv++MDV毒株细胞变化的保护效果有限
Nagwa Khaled,Carissa Gaghan,Abdelhamid M Fares et al.
Nagwa Khaled et al.
Very virulent plus (vv+) Marek's disease virus (MDV) strains are highly immunosuppressive and cause marked alterations in splenic immune cell populations in commercial meat-type (MT) chickens, even in the presence of maternal antibodies. In...
Geospatial approaches for mapping zero-dose prevalence and routine childhood immunisation coverage in low- and lower-middle-income countries: A scoping review [0.03%]
低收入和中低收入国家儿童常规免疫接种覆盖率和零剂量疫苗覆盖率的地理空间制图法：系统综述
Ann M Njogu,Moses M Musau,Swati Srivastava et al.
Ann M Njogu et al.
Background: Zero-dose (ZD) children remain a critical public health concern, particularly in low- and lower-middle-income countries (LLMICs), where over 80% of the global ZD population resides, disproportionately concentr...
Comment on "Effect of pneumococcal conjugate vaccine booster dose on prevention of invasive pneumococcal disease in British Columbia, 2003-2018" [0.03%]
关于“肺炎球菌结合疫苗加强剂对2003-2018年加拿大不列颠哥伦比亚省侵袭性肺炎球菌病的预防作用的影响”的评论
Bhumesh Tyagi,Leelabati Toppo,Aishwarya Biradar
Bhumesh Tyagi